APLM vs. SCYX, BRNS, IFRX, BNTC, CMRX, TLSA, VTVT, ASMB, ONCY, and PYRGF
Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include SCYNEXIS (SCYX), Barinthus Biotherapeutics (BRNS), InflaRx (IFRX), Benitec Biopharma (BNTC), Chimerix (CMRX), Tiziana Life Sciences (TLSA), vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), Oncolytics Biotech (ONCY), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical preparations" industry.
SCYNEXIS (NASDAQ:SCYX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
SCYNEXIS has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
SCYNEXIS has a net margin of 72.18% compared to SCYNEXIS's net margin of 0.00%. Apollomics' return on equity of 112.89% beat SCYNEXIS's return on equity.
SCYNEXIS presently has a consensus price target of $15.00, indicating a potential upside of 521.12%. Apollomics has a consensus price target of $2.00, indicating a potential upside of 571.14%. Given SCYNEXIS's higher probable upside, analysts clearly believe Apollomics is more favorable than SCYNEXIS.
SCYNEXIS received 501 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 70.24% of users gave SCYNEXIS an outperform vote.
In the previous week, SCYNEXIS and SCYNEXIS both had 3 articles in the media. Apollomics' average media sentiment score of 1.20 beat SCYNEXIS's score of 0.96 indicating that SCYNEXIS is being referred to more favorably in the media.
SCYNEXIS has higher revenue and earnings than Apollomics.
Summary
SCYNEXIS beats Apollomics on 9 of the 13 factors compared between the two stocks.
Get Apollomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apollomics Competitors List
Related Companies and Tools
